Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma

Abstract

Natural killer-like T lymphocytes termed cytokine-induced killer (CIK) cells have been shown to eradicate established tumours in a severe combined immune deficient (SCID) mouse/human lymphoma model. Recently, we demonstrated that CIK cells transfected with cytokine genes possess an improved proliferation rate and a significantly higher cytotoxic activity as compared to non-transfected cells. Here, in a phase I clinical protocol, autologous CIK cells were generated from peripheral blood obtained by leukapheresis in patients with metastatic renal cell carcinoma, colorectal carcinoma and lymphoma. CIK cells were transfected with a plasmid containing the interleukin-2 (IL-2) gene via electroporation. Transfected cells generated IL-2 in the range of 330-1800 pg 10(-6) cells 24 h(-1) with a mean of 836 pg 10(-6) cells 24 h(-1). Ten patients received 1-5 intravenous infusions of IL-2-transfected CIK cells; five infusions with transfected CIK cells were given. In addition, the same patients received five infusions with untransfected CIK cells for control reasons. In three patients, WHO grade 2 fever was observed. Based on polymerase chain reaction of peripheral blood transfected cells could be detected for up to 2 weeks after infusion. There was a significant increase in serum levels of interferon gamma (IFN-gamma), granulocyte-macrophage colony-stimulating factor (GM-CSF) and transforming growth factor beta (TGF-beta) during treatment. Interestingly, there was also an increase in CD3+ lymphocytes in the blood of patients during therapy. In accordance, a partial increase in cytotoxic activity in peripheral blood lymphocytes (PBLs) was documented when patient samples before and after therapy were compared. Concerning clinical outcome, six patients remained in progressive disease, three patients showed no change by treatment, and one patient with lymphoma developed a complete response. In conclusion, we were able to demonstrate that CIK cells transfected with the IL-2 gene can be administered without major side-effects and are promising for future therapeutic trials.

References 24

1. 1.

   Buschle M., Cotten M., Kirlappos H., Mechtler K., Schaffner G., Zauner W., Birnstiel M. L., Wagner E. Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. Hum Gene Ther. 1995;6(6):753-761.

   Not in our library10.1089/hum.1995.6.6-753

2. 2.

   Ebert O., Finke S., Salahi A., Herrmann M., Trojaneck B., Lefterova P., Wagner E., Kircheis R., Huhn D., Schriever F. Lymphocyte apoptosis: induction by gene transfer techniques. Gene Ther. 1997;4(4):296-302.

   Not in our library10.1038/sj.gt.3300394

3. 3.

   Finke S., Trojaneck B., Lefterova P., Csipai M., Wagner E., Kircheis R., Neubauer A., Huhn D., Wittig B., Schmidt-Wolf I. G. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther. 1998;5(1):31-39.

   Not in our library10.1038/sj.gt.3300560

4. 4.

   Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823-1841.

   Not in our library10.1084/jem.155.6.1823

5. 5.

   Hickman C. J., Crim J. A., Mostowski H. S., Siegel J. P. Regulation of human cytotoxic T lymphocyte development by IL-7. J Immunol. 1990;145(8):2415-2420.

   Not in our library

6. 6.

   Hwu P., Yannelli J., Kriegler M., Anderson W. F., Perez C., Chiang Y., Schwarz S., Cowherd R., Delgado C., Mulé J. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol. 1993;150(9):4104-4115.

   Not in our library

7. 7.

   Lotze M. T., Grimm E. A., Mazumder A., Strausser J. L., Rosenberg S. A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41(11 Pt 1):4420-4425.

   Not in our library

8. 8.

   Lu P. H., Negrin R. S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153(4):1687-1696.

   Not in our library

9. 9.

   Lynch D. H., Miller R. E. Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol. 1990;145(6):1983-1990.

   Not in our library

10. 10.

    Margolin K. A., Negrin R. S., Wong K. K., Chatterjee S., Wright C., Forman S. J. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev. 1997;157:231-240.

    Not in our library10.1111/j.1600-065x.1997.tb00986.x

11. 11.

    Markowitz S. D., Roberts A. B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996;7(1):93-102.

    Not in our library10.1016/1359-6101(96)00001-9

12. 12.

    Mehta B. A., Schmidt-Wolf I. G., Weissman I. L., Negrin R. S. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood. 1995;86(9):3493-3499.

    Not in our library

13. 13.

    Ramp U., Jaquet K., Reinecke P., Nitsch T., Gabbert H. E., Gerharz C. D. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest. 1997;76(5):739-749.

    Not in our library

14. 14.

    Riedl E., Strobl H., Majdic O., Knapp W. TGF-beta 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J Immunol. 1997;158(4):1591-1597.

    Not in our library

15. 15.

    Rosenberg S. A., Aebersold P., Cornetta K., Kasid A., Morgan R. A., Moen R., Karson E. M., Lotze M. T., Yang J. C., Topalian S. L. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323(9):570-578.

    Not in our library10.1056/nejm199008303230904

16. 16.

    Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318-1321.

    Not in our library10.1126/science.3489291

17. 17.

    Schmidt-Wolf G. D., Negrin R. S., Schmidt-Wolf I. G. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol. 1997;74(2):51-56.

    Not in our library10.1007/s002770050257

18. 18.

    Schmidt-Wolf G. D., Schmidt-Wolf I. G. Cancer and gene therapy. Ann Hematol. 1996;73(5):207-218.

    Not in our library10.1007/s002770050231

19. 19.

    Schmidt-Wolf I. G., Huhn D., Neubauer A., Wittig B. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Hum Gene Ther. 1994;5(9):1161-1168.

    Not in our library10.1089/hum.1994.5.9-1161

20. 20.

    Schmidt-Wolf I. G., Lefterova P., Johnston V., Huhn D., Blume K. G., Negrin R. S. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994;87(3):453-458.

    Not in our library10.1111/j.1365-2141.1994.tb08297.x

21. 21.

    Schmidt-Wolf I. G., Negrin R. S., Kiem H. P., Blume K. G., Weissman I. L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139-149.

    Not in our library10.1084/jem.174.1.139

22. 22.

    Welch P. A., Namen A. E., Goodwin R. G., Armitage R., Cooper M. D. Human IL-7: a novel T cell growth factor. J Immunol. 1989;143(11):3562-3567.

    Not in our library

23. 23.

    Wright J. A., Huang A. Growth factors in mechanisms of malignancy: roles for TGF-beta and FGF. Histol Histopathol. 1996;11(2):521-536.

    Not in our library

24. 24.

    Zoll B., Lefterova P., Csipai M., Finke S., Trojaneck B., Ebert O., Micka B., Roigk K., Fehlinger M., Schmidt-Wolf G. D. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother. 1998;47(4):221-226.

    Not in our library10.1007/s002620050524

Cited by papers we hold 3

• Cell Therapy: Types, Regulation, and Clinical Benefits · 2021
  No notice
• Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer · 2020
  Not checked
• Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.